Lineage Cell Therapeutics, Inc. LCTX
1.03
0.08
8.42%
as of 25 Sep
- Market cap
- $239.7M
- P/E
- 0.0×
Follow LCTX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (60.35%) | (98.51%) | (105.57%) | (158.10%) |
+8 more TTM periods Free account |
|
| (32.75%) | (58.03%) | (56.27%) | (72.66%) | ||
ROIC |
(186.79%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(67.96%) | (127.11%) | (126.17%) | (193.11%) | |
Average Days of Receivables |
22.04 | 19.91 | 22.34 | 4.29 | |
Free Cash Flow per Share |
(0.10) | (0.09) | (0.08) | (0.09) | |
Free Cash Flow |
(24.39) | (22.59) | (19.44) | (20.87) | |
Capital Expenditures |
(0.57) | (0.48) | (0.52) | (0.49) | |
Piotroski F-Score |
6.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(21.53%) | (20.84%) | (19.08%) | (33.25%) | |
Accounts Receivable Turnover |
25.02 | 29.01 | 19.04 | 40.66 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.02 | 0.05 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 17,952.50 | 7,097.22 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
156.82% | 127.54% | 121.80% | 119.40% | |
Selling, General and Administrative Expense of Revenue |
147.86% | 126.44% | 126.82% | 166.50% | |
Share Based Compensation of Revenue |
38.75% | 31.85% | 32.65% | 45.94% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.34 | 0.30 | 0.30 | |
Depreciation/Fixed assets |
0.33 | 6.21 | 6.03 | 7.16 | |
Capex/Depreciation |
(0.70) | (0.03) | (0.03) | (0.03) | |
Revenue per Share |
0.05 | 0.06 | 0.06 | 0.05 | |
Operating CF per Share |
(0.10) | (0.09) | (0.08) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.04 | 0.05 | |
Net Profit Margin |
(246.58%) | (434.44%) | (436.47%) | (625.53%) |
Columns are period end dates